Natural History and Treatment of Low and High Risk Superficial Bladder Tumors
1988; Lippincott Williams & Wilkins; Volume: 139; Issue: 2 Linguagem: Inglês
10.1016/s0022-5347(17)42387-1
ISSN1527-3792
AutoresH. Rübben, Wolfgang Lutzeyer, N. Fischer, F.-J. Deutz, Willi Lagrange, Guido Giani,
Tópico(s)Renal cell carcinoma treatment
ResumoNo AccessJournal of Urology1 Feb 1988Natural History and Treatment of Low and High Risk Superficial Bladder Tumors Herbert Rübben, Wolfgang Lutzeyer, Norbert Fischer, Friedrich Deutz, Willi Lagrange, Guido Giani, and Members of the Registry for Urinary Tract Tumors, Rheinisch Westfälische Technische Hochschule, Aachen Herbert RübbenHerbert Rübben More articles by this author , Wolfgang LutzeyerWolfgang Lutzeyer More articles by this author , Norbert FischerNorbert Fischer More articles by this author , Friedrich DeutzFriedrich Deutz More articles by this author , Willi LagrangeWilli Lagrange More articles by this author , Guido GianiGuido Giani More articles by this author , and Members of the Registry for Urinary Tract Tumors, Rheinisch Westfälische Technische Hochschule, Aachen More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)42387-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Since 1979 a prospective randomized trial was done to examine the efficacy of intravesical doxorubicin as prophylaxis against recurrence. After complete transurethral resection of the tumor, patients were divided into 3 groups at random: group 1—no further treatment after transurethral resection, group 2—doxorubicin twice weekly for 6 weeks and group 3—doxorubicin for 1 year. A total of 268 patients entered the study. Neither frequency of recurrences, tumor progression nor survival rate was improved significantly by the adjuvant treatment, so that only a limited number of patients will profit by instillation therapy. Analysis of previously reported data suggests that patients with superficial bladder tumors can be stratified into groups with appreciable differences in risk of progression. With regard to these results a differentiated use of a “wait and see” adjuvant intravesical therapy and more aggressive treatment after transurethral resection of superficial bladder tumors seems to be indicated rather than a general practice of chemoprophylaxis. © 1988 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByZhang S, Zhong G, He W, Yu H, Huang J and Lin T (2018) lncRNA Up-Regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of RecurrenceJournal of Urology, VOL. 196, NO. 4, (1270-1278), Online publication date: 1-Oct-2016.Li H, Wang J, Xiao W, Xia D, Lang B, Wang T, Guo X, Hu Z, Ye Z and Xu H (2013) Epigenetic Inactivation of KLF4 is Associated with Urothelial Cancer Progression and Early RecurrenceJournal of Urology, VOL. 191, NO. 2, (493-501), Online publication date: 1-Feb-2014.LOTAN Y and ROEHRBORN C (2018) COST-EFFECTIVENESS OF A MODIFIED CARE PROTOCOL SUBSTITUTING BLADDER TUMOR MARKERS FOR CYSTOSCOPY FOR THE FOLLOWUP OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A DECISION ANALYTICAL APPROACHJournal of Urology, VOL. 167, NO. 1, (75-79), Online publication date: 1-Jan-2002.Soloway M, Sofer M and Vaidya A (2018) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, VOL. 167, NO. 4, (1573-1583), Online publication date: 1-Apr-2002.HOLMANG S, HEDELIN H, ANDERSTROM C, HOLMBERG E, BUSCH C and JOHANSSON S (2018) RECURRENCE AND PROGRESSION IN LOW GRADE PAPILLARY UROTHELIAL TUMORSJournal of Urology, VOL. 162, NO. 3 Part 1, (702-707), Online publication date: 1-Sep-1999.LINN J, SESTERHENN I, MOSTOFI F and SCHOENBERG M (2018) THE MOLECULAR CHARACTERISTICS OF BLADDER CANCER IN YOUNG PATIENTSJournal of Urology, VOL. 159, NO. 5, (1493-1496), Online publication date: 1-May-1998.BELLDEGRUN A, FRANKLIN J, O'DONNELL M, GOMELLA L, KLEIN E, NERI R, NSEYO U, RATLIFF T and WILLIAMS R (2018) SUPERFICIAL BLADDER CANCER: THE ROLE OF INTERFERON-alphaJournal of Urology, VOL. 159, NO. 6, (1793-1801), Online publication date: 1-Jun-1998.Lamm D, Riggs D, Traynelis C and Nseyo U (2018) Apparent Failure of Current Intravesical Chemotherapy Prophylaxis to Influence the Long-Term Course of Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 153, NO. 5, (1444-1450), Online publication date: 1-May-1995.Soloway M (2018) Editorial: Intravesical Therapy for Bladder CancerJournal of Urology, VOL. 152, NO. 2 Part 1, (379-381), Online publication date: 1-Aug-1994.Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff J, Huber C and Hohenfellner R (2018) Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective StudyJournal of Urology, VOL. 148, NO. 2 Part 1, (302-306), Online publication date: 1-Aug-1992.Prout G, Barton B, Griffin P and Friedell G (2018) Treated History of Noninvasive Grade 1 Transitional Cell CarcinomaJournal of Urology, VOL. 148, NO. 5 Part 1, (1413-1419), Online publication date: 1-Nov-1992.Levi D’Ancona C, Rodrigues Netto N, Almeida Claro J and Ikari O (2018) Oral or Intravesical Bacillus Calmette-Guerin Immunoprophylaxis in Bladder CarcinomaJournal of Urology, VOL. 145, NO. 3, (498-501), Online publication date: 1-Mar-1991.Steinberg G, Brendler C, Squire R and Isaacs J (2018) Experimental Intravesical Therapy for Superficial Transitional Cell Carcinoma in a Rat Bladder Tumor ModelJournal of Urology, VOL. 145, NO. 3, (647-653), Online publication date: 1-Mar-1991.Stewart D, Green R, Futter N, Walsh W, Mckay D, Verma S, Maroun J and Redmond D (2018) Phase I and Pharmacology Study of Intravesical Mitoxantrone for Recurrent Superficial Bladder TumorsJournal of Urology, VOL. 143, NO. 4, (714-716), Online publication date: 1-Apr-1990.Soloway M (2018) Editorial CommentsJournal of Urology, VOL. 143, NO. 4, (716-716), Online publication date: 1-Apr-1990.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 143, NO. 4, (716-716), Online publication date: 1-Apr-1990.Kirkels W, Feitz W, Verhagen-Derks W, Herman C and Debruyne F (2018) The Predictive Value of Repeated Urine Cell Culture in Soft Agar for Recurrences of Transitional Cell CarcinomaJournal of Urology, VOL. 142, NO. 2 Part 1, (422-424), Online publication date: 1-Aug-1989.Mitchell I, Hayward S, Deshpande N and Towler J (2018) Enzyme Studies in Human Transitional Cell Carcinoma of the Urinary BladderJournal of Urology, VOL. 141, NO. 5, (1234-1237), Online publication date: 1-May-1989.Kim H and Lee C (2018) Intravesical Mitomycin C Instillation as a Prophylactic Treatment of Superficial Bladder TumorJournal of Urology, VOL. 141, NO. 6, (1337-1339), Online publication date: 1-Jun-1989. Volume 139Issue 2February 1988Page: 283-285 Advertisement Copyright & Permissions© 1988 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Herbert Rübben More articles by this author Wolfgang Lutzeyer More articles by this author Norbert Fischer More articles by this author Friedrich Deutz More articles by this author Willi Lagrange More articles by this author Guido Giani More articles by this author Members of the Registry for Urinary Tract Tumors, Rheinisch Westfälische Technische Hochschule, Aachen More articles by this author Expand All Advertisement Loading ...
Referência(s)